Breast cancer detection with short-interval follow-up compared with return to annual screening in patients with benign stereotactic or US-guided breast biopsy results

Jason M. Johnson, Alisa K. Johnson, Ellen S. O'Meara, Diana L Miglioretti, Berta M. Geller, Elise N. Hotaling, Sally D. Herschorn

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To compare the cancer detection rate and stage after benign stereotactic or ultrasonography (US)-guided core breast biopsy between patients with short-interval follow-up (SIFU) and those who return to annual screening. Materials and Methods: The Breast Cancer Surveillance Consortium (BCSC) registry and the BCSC Statistical Coordinating Center received institutional review board approval for active and passive consent processes and a waiver of consent. All procedures were HIPAA compliant. BCSC data for 1994-2010 were used to compare ipsilateral breast cancer detection rates and tumor characteristics for diagnoses within 3 months after SIFU (3-8 months) versus return to annual screening (RTAS) mammography (9-18 months) after receiving a benign pathology result from image-guided breast biopsy. Results: In total, 17 631 biopsies with benign findings were identified with SIFU or RTAS imaging. In the SIFU group, 27 ipsilateral breast cancers were diagnosed in 10 715 mammographic examinations (2.5 cancers per 1000 examinations) compared with 16 cancers in 6916 mammographic examinations in the RTAS group (2.3 cancers per 1000 examinations) (P =.88). Sixteen cancers after SIFU (59%; 95% confidence interval [CI]: 39%, 78%) were invasive versus 12 after RTAS (75%; 95% CI: 48%, 93%). The invasive cancer rate was 1.5 per 1000 examinations after SIFU (95% CI: 0.9, 2.4) and 1.7 per 1000 examinations (95% CI: 0.9, 3.0) after RTAS (P =.70). Among invasive cancers, 25% were late stage (stage 2B, 3, or 4) in the SIFU group (95% CI: 7%, 52%) versus 27% in the RTAS group (95% CI: 6%, 61%). Positive lymph nodes were found in seven (44%; 95% CI: 20%, 70%) invasive cancers after SIFU and in three (25%; 95% CI: 5%, 57%) invasive cancers after RTAS. Conclusion: Similar rates of cancer detection were found between SIFU and RTAS after benign breast biopsy with no significant differences in stage, tumor size, or nodal status, although the present study was limited by sample size. These findings suggest that patients with benign radiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.

Original languageEnglish (US)
Pages (from-to)54-60
Number of pages7
JournalRadiology
Volume275
Issue number1
DOIs
StatePublished - Apr 1 2015

Fingerprint

Mammary Ultrasonography
Breast Neoplasms
Biopsy
Confidence Intervals
Neoplasms
Breast
Image-Guided Biopsy
Health Insurance Portability and Accountability Act
Research Ethics Committees
Mammography
Sample Size
Registries

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Breast cancer detection with short-interval follow-up compared with return to annual screening in patients with benign stereotactic or US-guided breast biopsy results. / Johnson, Jason M.; Johnson, Alisa K.; O'Meara, Ellen S.; Miglioretti, Diana L; Geller, Berta M.; Hotaling, Elise N.; Herschorn, Sally D.

In: Radiology, Vol. 275, No. 1, 01.04.2015, p. 54-60.

Research output: Contribution to journalArticle

Johnson, Jason M. ; Johnson, Alisa K. ; O'Meara, Ellen S. ; Miglioretti, Diana L ; Geller, Berta M. ; Hotaling, Elise N. ; Herschorn, Sally D. / Breast cancer detection with short-interval follow-up compared with return to annual screening in patients with benign stereotactic or US-guided breast biopsy results. In: Radiology. 2015 ; Vol. 275, No. 1. pp. 54-60.
@article{89dc885d439349b0b0211897c54fd355,
title = "Breast cancer detection with short-interval follow-up compared with return to annual screening in patients with benign stereotactic or US-guided breast biopsy results",
abstract = "Purpose: To compare the cancer detection rate and stage after benign stereotactic or ultrasonography (US)-guided core breast biopsy between patients with short-interval follow-up (SIFU) and those who return to annual screening. Materials and Methods: The Breast Cancer Surveillance Consortium (BCSC) registry and the BCSC Statistical Coordinating Center received institutional review board approval for active and passive consent processes and a waiver of consent. All procedures were HIPAA compliant. BCSC data for 1994-2010 were used to compare ipsilateral breast cancer detection rates and tumor characteristics for diagnoses within 3 months after SIFU (3-8 months) versus return to annual screening (RTAS) mammography (9-18 months) after receiving a benign pathology result from image-guided breast biopsy. Results: In total, 17 631 biopsies with benign findings were identified with SIFU or RTAS imaging. In the SIFU group, 27 ipsilateral breast cancers were diagnosed in 10 715 mammographic examinations (2.5 cancers per 1000 examinations) compared with 16 cancers in 6916 mammographic examinations in the RTAS group (2.3 cancers per 1000 examinations) (P =.88). Sixteen cancers after SIFU (59{\%}; 95{\%} confidence interval [CI]: 39{\%}, 78{\%}) were invasive versus 12 after RTAS (75{\%}; 95{\%} CI: 48{\%}, 93{\%}). The invasive cancer rate was 1.5 per 1000 examinations after SIFU (95{\%} CI: 0.9, 2.4) and 1.7 per 1000 examinations (95{\%} CI: 0.9, 3.0) after RTAS (P =.70). Among invasive cancers, 25{\%} were late stage (stage 2B, 3, or 4) in the SIFU group (95{\%} CI: 7{\%}, 52{\%}) versus 27{\%} in the RTAS group (95{\%} CI: 6{\%}, 61{\%}). Positive lymph nodes were found in seven (44{\%}; 95{\%} CI: 20{\%}, 70{\%}) invasive cancers after SIFU and in three (25{\%}; 95{\%} CI: 5{\%}, 57{\%}) invasive cancers after RTAS. Conclusion: Similar rates of cancer detection were found between SIFU and RTAS after benign breast biopsy with no significant differences in stage, tumor size, or nodal status, although the present study was limited by sample size. These findings suggest that patients with benign radiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.",
author = "Johnson, {Jason M.} and Johnson, {Alisa K.} and O'Meara, {Ellen S.} and Miglioretti, {Diana L} and Geller, {Berta M.} and Hotaling, {Elise N.} and Herschorn, {Sally D.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1148/radiol.14140036",
language = "English (US)",
volume = "275",
pages = "54--60",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Breast cancer detection with short-interval follow-up compared with return to annual screening in patients with benign stereotactic or US-guided breast biopsy results

AU - Johnson, Jason M.

AU - Johnson, Alisa K.

AU - O'Meara, Ellen S.

AU - Miglioretti, Diana L

AU - Geller, Berta M.

AU - Hotaling, Elise N.

AU - Herschorn, Sally D.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Purpose: To compare the cancer detection rate and stage after benign stereotactic or ultrasonography (US)-guided core breast biopsy between patients with short-interval follow-up (SIFU) and those who return to annual screening. Materials and Methods: The Breast Cancer Surveillance Consortium (BCSC) registry and the BCSC Statistical Coordinating Center received institutional review board approval for active and passive consent processes and a waiver of consent. All procedures were HIPAA compliant. BCSC data for 1994-2010 were used to compare ipsilateral breast cancer detection rates and tumor characteristics for diagnoses within 3 months after SIFU (3-8 months) versus return to annual screening (RTAS) mammography (9-18 months) after receiving a benign pathology result from image-guided breast biopsy. Results: In total, 17 631 biopsies with benign findings were identified with SIFU or RTAS imaging. In the SIFU group, 27 ipsilateral breast cancers were diagnosed in 10 715 mammographic examinations (2.5 cancers per 1000 examinations) compared with 16 cancers in 6916 mammographic examinations in the RTAS group (2.3 cancers per 1000 examinations) (P =.88). Sixteen cancers after SIFU (59%; 95% confidence interval [CI]: 39%, 78%) were invasive versus 12 after RTAS (75%; 95% CI: 48%, 93%). The invasive cancer rate was 1.5 per 1000 examinations after SIFU (95% CI: 0.9, 2.4) and 1.7 per 1000 examinations (95% CI: 0.9, 3.0) after RTAS (P =.70). Among invasive cancers, 25% were late stage (stage 2B, 3, or 4) in the SIFU group (95% CI: 7%, 52%) versus 27% in the RTAS group (95% CI: 6%, 61%). Positive lymph nodes were found in seven (44%; 95% CI: 20%, 70%) invasive cancers after SIFU and in three (25%; 95% CI: 5%, 57%) invasive cancers after RTAS. Conclusion: Similar rates of cancer detection were found between SIFU and RTAS after benign breast biopsy with no significant differences in stage, tumor size, or nodal status, although the present study was limited by sample size. These findings suggest that patients with benign radiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.

AB - Purpose: To compare the cancer detection rate and stage after benign stereotactic or ultrasonography (US)-guided core breast biopsy between patients with short-interval follow-up (SIFU) and those who return to annual screening. Materials and Methods: The Breast Cancer Surveillance Consortium (BCSC) registry and the BCSC Statistical Coordinating Center received institutional review board approval for active and passive consent processes and a waiver of consent. All procedures were HIPAA compliant. BCSC data for 1994-2010 were used to compare ipsilateral breast cancer detection rates and tumor characteristics for diagnoses within 3 months after SIFU (3-8 months) versus return to annual screening (RTAS) mammography (9-18 months) after receiving a benign pathology result from image-guided breast biopsy. Results: In total, 17 631 biopsies with benign findings were identified with SIFU or RTAS imaging. In the SIFU group, 27 ipsilateral breast cancers were diagnosed in 10 715 mammographic examinations (2.5 cancers per 1000 examinations) compared with 16 cancers in 6916 mammographic examinations in the RTAS group (2.3 cancers per 1000 examinations) (P =.88). Sixteen cancers after SIFU (59%; 95% confidence interval [CI]: 39%, 78%) were invasive versus 12 after RTAS (75%; 95% CI: 48%, 93%). The invasive cancer rate was 1.5 per 1000 examinations after SIFU (95% CI: 0.9, 2.4) and 1.7 per 1000 examinations (95% CI: 0.9, 3.0) after RTAS (P =.70). Among invasive cancers, 25% were late stage (stage 2B, 3, or 4) in the SIFU group (95% CI: 7%, 52%) versus 27% in the RTAS group (95% CI: 6%, 61%). Positive lymph nodes were found in seven (44%; 95% CI: 20%, 70%) invasive cancers after SIFU and in three (25%; 95% CI: 5%, 57%) invasive cancers after RTAS. Conclusion: Similar rates of cancer detection were found between SIFU and RTAS after benign breast biopsy with no significant differences in stage, tumor size, or nodal status, although the present study was limited by sample size. These findings suggest that patients with benign radiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.

UR - http://www.scopus.com/inward/record.url?scp=84926475820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926475820&partnerID=8YFLogxK

U2 - 10.1148/radiol.14140036

DO - 10.1148/radiol.14140036

M3 - Article

C2 - 25423143

AN - SCOPUS:84926475820

VL - 275

SP - 54

EP - 60

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -